Bio­haven touts surge in Nurtec sales ahead of Pfiz­er takeover

For­get buy­er’s re­morse, Pfiz­er is like­ly feel­ing pret­ty good about its $11.6 bil­lion Bio­haven takeover deal fol­low­ing re­ports of a 57% sales boost for mi­graine med Nurtec.

Bio­haven re­port­ed in Q2 re­sults on Fri­day that it’s cleared the nec­es­sary an­titrust hur­dles to move for­ward with the sale of its cal­ci­tonin gene-re­lat­ed pep­tide (CGRP) as­sets to Pfiz­er. How­ev­er, be­cause the com­pa­ny is “fo­cused on work­streams re­lat­ed to the clos­ing” of the deal, it did not host a call with an­a­lysts and in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER